Seshadri Neervannan
CIK: 0001827584
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Tarsus Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Sep 4, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct4.6K shares at avg. $85.00$388K - Mar 20, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3K shares at avg. $66.75$200K - Mar 19, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct4.6K shares at avg. $67.00$307K - Mar 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.6K shares at avg. $68.71$248K - Mar 17, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.1K shares at avg. $69.42$217K - Mar 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct26.3K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
17.2K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
27.3K shares- - Mar 4, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct8.4K shares at avg. $76.67$641K - Dec 16, 2025TARS
Tarsus Pharmaceuticals, Inc.
Gift(G)Direct950 shares- - Dec 16, 2025TARS
Tarsus Pharmaceuticals, Inc.
Gift(G)Indirect475 shares- - Mar 20, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.4K shares at avg. $50.11$122K - Mar 19, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.5K shares at avg. $47.40$121K - Mar 18, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.6K shares at avg. $46.29$121K - Mar 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct21.3K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30.6K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
20.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,564 | $85.00 | $387,940 | Direct |
| Mar 20, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,989 | $66.75 | $199,516 | Direct |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,589 | $67.00 | $307,463 | Direct |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,610 | $68.71 | $248,043 | Direct |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,125 | $69.42 | $216,938 | Direct |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 26,287 | - | $0 | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 17,161 | - | - | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 27,310 | - | - | Direct |
| Mar 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 8,366 | $76.67 | $641,421 | Direct |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Gift(G) | 950 | - | - | Direct |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Gift(G) | 475 | - | - | Indirect |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,435 | $50.11 | $122,018 | Direct |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,543 | $47.40 | $120,538 | Direct |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,605 | $46.29 | $120,585 | Direct |
| Mar 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 21,264 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,628 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 20,089 | - | - | Direct |
1-17 of 17 transactions
About Neervannan Seshadri
Neervannan Seshadri (SEC CIK 0001827584) files insider reports with the SEC as Chief Operating Officer of Tarsus Pharmaceuticals, Inc. (TARS).
Signal8 holds 10 ownership filings by Neervannan Seshadri, all Form 4s, filed between Mar 7, 2025 and Sep 9, 2026. Those filings report 17 transactions, from Mar 5, 2025 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Neervannan Seshadri's filings is in IRVINE, CA.
Recent filings by Neervannan Seshadri
- Sep 4, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 20, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 19, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 18, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 17, 2026: Open-market sale of TARS shares (Form 4, code S).
Other insiders filing for Tarsus Pharmaceuticals, Inc. (TARS)
- PYOTT DAVID E I, Director
- YARNO WENDY L, Director
- LINK WILLIAM J PHD, Director
- Azamian Bobak R., President/CEO and Board Chair
- Lin Elizabeth Yeu, Chief Medical Officer
- Goodrich Katherine, Director